Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas

Leukemia

Volumn 20, Issue 9, 2006, Pages 1593-1601

  Ringrose, A ^a   Zhou, Y ^b,c   Pang, E ^a   Zhou, L ^a   Lin, A E J ^a   Sheng, G ^d   Li, X J ^d   Weng, A ^a,c   Su, M W ^c   Pittelkow, M R ^e   Jiang, X ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON HELPER INTEGRATION SITE 1; GROWTH FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; ISOPROTEIN; ONCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEREGULATION; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKEMOGENESIS; LYMPHOMA CELL LINE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETROVIRUS; RNA INTERFERENCE; SEZARY SYNDROME; T CELL LYMPHOMA;

EID: 33747604592     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404321     Document Type: Article

References (47)

1. Jiang X, Hanna Z, Kaouass M, Girard L, Jolicoeur P. Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations. J Virol 2002; 76: 9046-9059.
2. D/myc transgenic mice suggests a callaboration of c-myc and Notch1 for oncogenesis. Genes Dev 1996; 10: 1930-1944.
3. Villeneuve L, Jiang X, Turmel C, Kozak CA, Jolicoeur P. Long-range mapping of Mis-2, a common provirus integration site identified in murine leukemia virus-induced thymomas and located 160 kilobase pairs downstream of Myb. J Virol 1993; 67: 5733-5739.
4. Blaydes SM, Kogan SC, Truong BT, Gilbert DJ, Jenkins NA, Copeland NG et al. Retroviral integration at the Epil locus cooperates with Nfl gene loss in the progression to acute myeloid leukemia. J Virol 2001; 75: 9427-9434.
5. + human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. Blood 2004; 103: 3897-3904.
6. Foss F. Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol 2004; 16: 421-428.
7. Vonderheid EC, Bernengo MG. The Sezary syndrome: Hematologic criteria. Hematol Oncol Clin N Am 2003; 17: 1367-1389.
8. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
9. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S et al. EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer. Blood 1997; 90: 354-371.
10. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996; 93: 9148-9153.
11. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C et al. Constitutive STAT3-activation in Sezary syndrome: Tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001; 15: 787-793.
12. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18: 1288-1295.
13. Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C etal. Classification and prediction ofsurvival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477-1488.
14. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003; 101: 1513-1519.
15. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 6002-6006.
16. Zhang Q, Capocasale RJ, Fox FE, Bedian V, Vonderheid EC, Rook A et al. Diminished expression of the type II receptor for TGFbeta (TGFbetaRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: Limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeric base stretches. Arch Immunol Ther Exp (Warsz) 2002; 50: 421-429.
17. Dereure O, Levi E, Vonderheid EC, Kadin ME. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: A possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 2002; 118: 949-956.
18. Karenko L, Hyytinen E, Sarna S, Ranki A. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol 1997; 108: 22-29.
19. Mao X, Lillington D, Scarisbrick JJ, Mitchell T, Czepulkowski B, Russell-Jones R et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: Identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol 2002; 147: 464-475.
20. McGregor JM, Crook T, Fraser-Andrews EA, Rozycka M, Crossland S, Brooks L et al. Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol 1999; 112: 317-321.
21. Barton GM, Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA 2002; 99: 14943-14945.
22. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247.
23. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
24. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405-1413.
25. BCR-ABL activity in transduced primary human hematopoietic cells controls lineage reprogramming. Blood 2002; 99: 3197-3204.
26. Su MW, Dorocicz I, Dragowska WH, Ho V, Li G, Voss N et al. Aberrant expression of T-plastin in Sezary cells. Cancer Res 2003; 63: 7122-7127.
27. Jiang X, Ng E, Yip C, Eisterer W, Chalandon Y, Stuible M et al. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood 2002; 100: 3731-3740.
28. Jiang X, Stuible M, Chalandon Y, Li A, Chan WY, Eisterer W et al. Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 2003; 102: 2976-2984.
29. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R et al. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci 1999; 19: 2522-2534.
30. Eaves CJ. Assays of hemopoietic progenitor cells. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds). Williams Hematology, Vol. 5, McGraw-Hill, Inc.: New York, 1995, pp L22-L26.
31. 2-microglobulin-deficient NOD-SCID mice. J Immunol 1997; 158:3578-3586.
32. O'Connell MA, Cleere R, Long A, O'Neill LA, Kelleher D. Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78. J Biol Chem 1995; 270: 7399-7404.
33. Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, Gallo RC. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 1981; 154: 1403-1418.
34. Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 1980; 55: 409-417.
35. Wood GS, Hong SR, Sasaki DT, Abel EA, Hoppe PT, Warnke RA et al. Leu-8/ CD7 antigen expression by CD3+ T cells: Comparative analysis of skin and blood in mycosis fungoides/Sezary syndrome relative to normal blood values. J Am Acad Dermatol 1990; 22: 602-607.
36. Bagot M, Charue D, Boulland ML, Gaulard P, Revuz J, Schmitt C et al. Interleukin-7 receptor expression in cutaneous T-cell lymphomas. Br J Dermatol 1996; 135: 572-575.
37. Dykxchoorn DM, Novina CD, Sharp PA. Killing the messenger: Short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4: 457-467.
38. Hehlgan T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology 2005; 115: 1-20.
39. Schulz U, Munker R, Ertl B, Holler E, Kolb HJ. Different types of human leukemias express the message for TNF-alpha and interleukin-10. Eur J Med Res 2001; 6: 359-363.
40. Behringer D, Schaufler J, Kresin V, Lubbert M, Lindemann A. Differentiation associated modulation of the cytokine and chemokine expression pattern in human myeloid cell lines. Leukemia Res 2001; 25: 141-149.
41. Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K et al. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 2005; 203: 387-397.
42. Tracey L, Villuendas R, Dotor AM, Spiteri I, Ortiz P, Garcia JF et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: An expression profile study. Blood 2003; 102: 1042-1050.
43. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996; 132: 42-47.
44. Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams JT, Bigler RD et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 207-220.
45. Ferland RJ, Eyaid W, Collura RV, Tully LD, Hill PS, Al Nouri D et al. Corrigendum: Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome. Nat Genet 2004; 36: 1008-1013.
46. Dixon-Salazar T, Silhavy JL, Marsh SE, Louie CM, Scott LC, Gururaj A et al. Mutations in the AHI1 gene, encoding jouberin, cause Joubert syndrome with cortical polymicrogyria. Am J Hum Genet 2004; 75: 979-987.
47. Valente EM, Brancati F, Silhavy JL, Castori M, Marsh SE, Barrano G et al. AHI1 gene mutations cause specific forms of Joubert syndrome-related disorders. Annu Neurol 2006; 59: 527-534.